Shelly, we appreciate the warning, but if you will look at the history of this board it has always been about Amarin and the broader topic of CV risk and it’s cure. All sorts of complementary drugs and procedures have always been discussed.
The CC call was strictly ho hum. AMRN needs a dynamic spokesman. JL is strictly a bean counter good with techical talk but as far as PR -not so much. This stock at $17 is a joke. For us longs- this is going to be really long unless the market comes to know what we know. They obviously dont. We need to hear about a European partner before Jan 1 or this stock is drifting downward and sideways
News 
Market Data 
Discover 
